Patents by Inventor Michael L. Metzker

Michael L. Metzker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130095471
    Abstract: Provided are novel nucleotides, nucleoside, and their derivatives described herein, that can be used in DNA sequencing technology and other types of DNA analysis. In one embodiment, the nucleotide or nucleoside with an unprotected 3?-OH group is derivatized at the nucleobase to include a fluorescent dye attached via a linker to a non-cleavable terminating group. The non-cleavable-fluorescent group is designed to terminate DNA synthesis so that DNA oligomers can be sequenced efficiently in a parallel format. These reagents and methods will lead to more accurate identification of polymorphisms and other valuable genetic information.
    Type: Application
    Filed: May 9, 2012
    Publication date: April 18, 2013
    Inventors: Weidong Wu, Vladislav A. Litosh, Brian P. Stupi, Michael L. Metzker
  • Publication number: 20130072388
    Abstract: Provided are novel nucleotides, nucleoside, and their derivatives described herein, that can be used in DNA sequencing technology and other types of DNA analysis. In one embodiment, the nucleotide or nucleoside with an unprotected 3?-OH group is derivatized at the nucleobase to include a fluorescent dye attached via a linker to a photocleavable terminating group. The photocleavable-fluorescent group is designed to terminate DNA synthesis as well as be cleaved so that DNA oligomers can be sequenced efficiently in a parallel format. The design of such rapidly cleavable fluorescent groups on nucleotides and nucleosides can enhance the speed and accuracy of sequencing of large oligomers of DNA in parallel, to allow rapid whole genome sequencing, and the identification of polymorphisms and other valuable genetic information, as well as allowing further manipulation and analysis of nucleic acid molecules in their native state following cleavage of the fluorescent group.
    Type: Application
    Filed: August 23, 2012
    Publication date: March 21, 2013
    Inventors: Weidong WU, Vladislav A. Litosh, Brian P. Stupi, Michael L. Metzker
  • Publication number: 20130035237
    Abstract: The present invention relates generally to labeled and unlabled cleavable terminating groups and methods for DNA sequencing and other types of DNA analysis. More particularly, the invention relates in part to nucleotides and nucleosides with chemically cleavable, photocleavable, enzymatically cleavable, or non-photocleavable groups and methods for their use in DNA sequencing and its application in biomedical research.
    Type: Application
    Filed: February 28, 2012
    Publication date: February 7, 2013
    Inventors: Vladislav A. Litosh, Megan N. Hersh, Brian P. Stupi, Weidong Wu, Michael L. Metzker
  • Patent number: 8361727
    Abstract: Provided are novel nucleotides, nucleoside, and their derivatives described herein, that can be used in DNA sequencing technology and other types of DNA analysis. In one embodiment, the nucleotide or nucleoside with an unprotected 3?-OH group is derivatized at the nucleobase to include a fluorescent dye attached via a linker to a photocleavable terminating group. The photocleavable-fluorescent group is designed to terminate DNA synthesis as well as be cleaved so that DNA oligomers can be sequenced efficiently in a parallel format. The design of such rapidly cleavable fluorescent groups on nucleotides and nucleosides can enhance the speed and accuracy of sequencing of large oligomers of DNA in parallel, to allow rapid whole genome sequencing, and the identification of polymorphisms and other valuable genetic information, as well as allowing further manipulation and analysis of nucleic acid molecules in their native state following cleavage of the fluorescent group.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: January 29, 2013
    Assignee: Lasergen, Inc.
    Inventors: Weidong Wu, Vladislav A. Litosh, Brian P. Stupi, Michael L. Metzker
  • Patent number: 8198029
    Abstract: Provided are novel nucleotides, nucleoside, and their derivatives described herein, that can be used in DNA sequencing technology and other types of DNA analysis. In one embodiment, the nucleotide or nucleoside with an unprotected 3?-OH group is derivatized at the nucleobase to include a fluorescent dye attached via a linker to a non-cleavable terminating group. The non-cleavable-fluorescent group is designed to terminate DNA synthesis so that DNA oligomers can be sequenced efficiently in a parallel format. These reagents and methods will lead to more accurate identification of polymorphisms and other valuable genetic information.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: June 12, 2012
    Assignee: Lasergen, Inc
    Inventors: Weidong Wu, Vladislav A. Litosh, Brian P. Stupi, Michael L. Metzker
  • Patent number: 8148503
    Abstract: The present invention relates generally to labeled and unlabled cleavable terminating groups and methods for DNA sequencing and other types of DNA analysis. More particularly, the invention relates in part to nucleotides and nucleosides with chemically cleavable, photocleavable, enzymatically cleavable, or non-photocleavable groups and methods for their use in DNA sequencing and its application in biomedical research.
    Type: Grant
    Filed: June 11, 2009
    Date of Patent: April 3, 2012
    Assignee: Lasergen, Inc.
    Inventors: Vladislav A. Litosh, Megan N. Hersh, Brian P. Stupi, Weidong Wu, Michael L. Metzker
  • Patent number: 8089628
    Abstract: The present invention provides a technology called Pulse-Multiline Excitation or PME. This technology provides a novel approach to fluorescence detection with application for high-throughput identification of informative SNPs, which could lead to more accurate diagnosis of inherited disease, better prognosis of risk susceptibilities, or identification of sporadic mutations. The PME technology has two main advantages that significantly increase fluorescence sensitivity: (1) optimal excitation of all fluorophores in the genomic assay and (2) “color-blind” detection, which collects considerably more light than standard wavelength resolved detection. Successful implementation of the PME technology will have broad application for routine usage in clinical diagnostics, forensics, and general sequencing methodologies and will have the capability, flexibility, and portability of targeted sequence variation assays for a large majority of the population.
    Type: Grant
    Filed: February 18, 2009
    Date of Patent: January 3, 2012
    Assignees: Baylor College of Medicine, Rice University
    Inventors: Graham B. I. Scott, Carter Kittrell, Robert F. Curl, Michael L. Metzker
  • Publication number: 20110287427
    Abstract: Provided are novel nucleotides, nucleoside, and their derivatives described herein, that can be used in DNA sequencing technology and other types of DNA analysis. In one embodiment, the nucleotide or nucleoside with an unprotected 3?-OH group is derivatized at the nucleobase to include a fluorescent dye attached via a linker to a photocleavable terminating group. The photocleavable-fluorescent group is designed to terminate DNA synthesis as well as be cleaved so that DNA oligomers can be sequenced efficiently in a parallel format. The design of such rapidly cleavable fluorescent groups on nucleotides and nucleosides can enhance the speed and accuracy of sequencing of large oligomers of DNA in parallel, to allow rapid whole genome sequencing, and the identification of polymorphisms and other valuable genetic information, as well as allowing further manipulation and analysis of nucleic acid molecules in their native state following cleavage of the fluorescent group.
    Type: Application
    Filed: May 24, 2011
    Publication date: November 24, 2011
    Applicant: LASERGEN, INC.
    Inventors: Weidong Wu, Vladislav A. Litosh, Brian P. Stupi, Michael L. Metzker
  • Publication number: 20110200988
    Abstract: Provided are novel nucleotides, nucleoside, and their derivatives described herein, that can be used in DNA sequencing technology and other types of DNA analysis. In one embodiment, the nucleotide or nucleoside with an unprotected 3?-OH group is derivatized at the nucleobase to include a fluorescent dye attached via a linker to a non-cleavable terminating group. The non-cleavable-fluorescent group is designed to terminate DNA synthesis so that DNA oligomers can be sequenced efficiently in a parallel format. These reagents and methods will lead to more accurate identification of polymorphisms and other valuable genetic information.
    Type: Application
    Filed: January 7, 2011
    Publication date: August 18, 2011
    Inventors: Weidong Wu, Vladislav A. Litosh, Brian P. Stupi, Michael L. Metzker
  • Patent number: 7964352
    Abstract: Provided are novel nucleotides, nucleoside, and their derivatives described herein, that can be used in DNA sequencing technology and other types of DNA analysis. In one embodiment, the nucleotide or nucleoside with an unprotected 3?-OH group is derivatized at the nucleobase to include a fluorescent dye attached via a linker to a photocleavable terminating group. The photocleavable-fluorescent group is designed to terminate DNA synthesis as well as be cleaved so that DNA oligomers can be sequenced efficiently in a parallel format. The design of such rapidly cleavable fluorescent groups on nucleotides and nucleosides can enhance the speed and accuracy of sequencing of large oligomers of DNA in parallel, to allow rapid whole genome sequencing, and the identification of polymorphisms and other valuable genetic information, as well as allowing further manipulation and analysis of nucleic acid molecules in their native state following cleavage of the fluorescent group.
    Type: Grant
    Filed: November 11, 2008
    Date of Patent: June 21, 2011
    Assignee: LaserGen, Inc.
    Inventors: Weidong Wu, Vladislav A. Litosh, Brian P. Stupi, Michael L. Metzker
  • Patent number: 7897737
    Abstract: Provided are novel nucleotides, nucleoside, and their derivatives described herein, that can be used in DNA sequencing technology and other types of DNA analysis. In one embodiment, the nucleotide or nucleoside with an unprotected 3?-OH group is derivatized at the nucleobase to include a fluorescent dye attached via a linker to a photocleavable terminating group. The photocleavable-fluorescent group is designed to terminate DNA synthesis as well as be cleaved so that DNA oligomers can be sequenced efficiently in a parallel format. The design of such rapidly cleavable fluorescent groups on nucleotides and nucleosides can enhance the speed and accuracy of sequencing of large oligomers of DNA in parallel, to allow rapid whole genome sequencing, and the identification of polymorphisms and other valuable genetic information, as well as allowing further manipulation and analysis of nucleic acid molecules in their native state following cleavage of the fluorescent group.
    Type: Grant
    Filed: December 5, 2006
    Date of Patent: March 1, 2011
    Assignee: LaserGen, Inc.
    Inventors: Weidong Wu, Vladislav A. Litosh, Brian P. Stupi, Michael L. Metzker
  • Patent number: 7893227
    Abstract: Provided are novel nucleotides, nucleoside, and their derivatives described herein, that can be used in DNA sequencing technology and other types of DNA analysis. In one embodiment, the nucleotide or nucleoside with an unprotected 3?-OH group is derivatized at the nucleobase to include a fluorescent dye attached via a linker to a non-cleavable terminating group. The non-cleavable-fluorescent group is designed to terminate DNA synthesis so that DNA oligomers can be sequenced efficiently in a parallel format. These reagents and methods will lead to more accurate identification of polymorphisms and other valuable genetic information.
    Type: Grant
    Filed: December 5, 2006
    Date of Patent: February 22, 2011
    Assignee: LaserGen, Inc.
    Inventors: Weidong Wu, Vladislav A. Litosh, Brian P. Stupi, Michael L. Metzker
  • Publication number: 20100041041
    Abstract: The present invention relates generally to labeled and unlabled cleavable terminating groups and methods for DNA sequencing and other types of DNA analysis. More particularly, the invention relates in part to nucleotides and nucleosides with chemically cleavable, photocleavable, enzymatically cleavable, or non-photocleavable groups and methods for their use in DNA sequencing and its application in biomedical research.
    Type: Application
    Filed: June 11, 2009
    Publication date: February 18, 2010
    Inventors: Vladislav A. LITOSH, Megan N. HERSH, Brian P. STUPI, Weidong WU, Michael L. METZKER
  • Patent number: 7511811
    Abstract: The present invention provides a technology called Pulse-Multiline Excitation or PME. This technology provides a novel approach to fluorescence detection with application for high-throughput identification of informative SNPs, which could lead to more accurate diagnosis of inherited disease, better prognosis of risk susceptibilities, or identification of sporadic mutations. The PME technology has two main advantages that significantly increase fluorescence sensitivity: (1) optimal excitation of all fluorophores in the genomic assay and (2) “color-blind” detection, which collects considerably more light than standard wavelength resolved detection. This technology differs significantly from the current state-of-the-art DNA sequencing instrumentation, which features single source excitation and color dispersion for DNA sequence identification.
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: March 31, 2009
    Assignee: Baylor College of Medicine and Rice University
    Inventors: Graham B. I. Scott, Carter Kittrell, Robert F. Curl, Michael L. Metzker
  • Publication number: 20090081686
    Abstract: Provided are novel nucleotides, nucleoside, and their derivatives described herein, that can be used in DNA sequencing technology and other types of DNA analysis. In one embodiment, the nucleotide or nucleoside with an unprotected 3?-OH group is derivatized at the nucleobase to include a fluorescent dye attached via a linker to a photocleavable terminating group. The photocleavable-fluorescent group is designed to terminate DNA synthesis as well as be cleaved so that DNA oligomers can be sequenced efficiently in a parallel format. The design of such rapidly cleavable fluorescent groups on nucleotides and nucleosides can enhance the speed and accuracy of sequencing of large oligomers of DNA in parallel, to allow rapid whole genome sequencing, and the identification of polymorphisms and other valuable genetic information, as well as allowing further manipulation and analysis of nucleic acid molecules in their native state following cleavage of the fluorescent group.
    Type: Application
    Filed: November 11, 2008
    Publication date: March 26, 2009
    Inventors: Weidong Wu, Vladislav A. Litosh, Brian P. Stupi, Michael L. Metzker
  • Publication number: 20080131952
    Abstract: Provided are novel nucleotides, nucleoside, and their derivatives described herein, that can be used in DNA sequencing technology and other types of DNA analysis. In one embodiment, the nucleotide or nucleoside with an unprotected 3?-OH group is derivatized at the nucleobase to include a fluorescent dye attached via a linker to a non-cleavable terminating group. The non-cleavable-fluorescent group is designed to terminate DNA synthesis so that DNA oligomers can be sequenced efficiently in a parallel format. These reagents and methods will lead to more accurate identification of polymorphisms and other valuable genetic information.
    Type: Application
    Filed: December 5, 2006
    Publication date: June 5, 2008
    Inventors: Weidong Wu, Vladislav A. Litosh, Brian P. Stupi, Michael L. Metzker
  • Publication number: 20080132692
    Abstract: Provided are novel nucleotides, nucleoside, and their derivatives described herein, that can be used in DNA sequencing technology and other types of DNA analysis. In one embodiment, the nucleotide or nucleoside with an unprotected 3?-OH group is derivatized at the nucleobase to include a fluorescent dye attached via a linker to a photocleavable terminating group. The photocleavable-fluorescent group is designed to terminate DNA synthesis as well as be cleaved so that DNA oligomers can be sequenced efficiently in a parallel format. The design of such rapidly cleavable fluorescent groups on nucleotides and nucleosides can enhance the speed and accuracy of sequencing of large oligomers of DNA in parallel, to allow rapid whole genome sequencing, and the identification of polymorphisms and other valuable genetic information, as well as allowing further manipulation and analysis of nucleic acid molecules in their native state following cleavage of the fluorescent group.
    Type: Application
    Filed: December 5, 2006
    Publication date: June 5, 2008
    Inventors: Weidong Wu, Vladislav A. Litosh, Brian P. Stupi, Michael L. Metzker
  • Patent number: 7361491
    Abstract: The present invention disclosed isolated nucleic acid molecules (polynucleotides) which encode NHL, a putative DNA helicase. The present invention in turn relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding NHL, substantially purified forms of associated NHL, associated mutant proteins, and methods associated with identifying compounds which modulate NHL, which will be useful in the treatment of various neoplastic disorders. Both a genomic clone containing regulatory and intron sequences, as well as the exon structure and open reading frame of human NHL are disclosed.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: April 22, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Xiaomei Liu, Chang Bai, Michael L. Metzker
  • Patent number: 7244577
    Abstract: A novel receptor, “LDL-receptor-related protein-5” (“LRP-5”), is provided, along with encoding nucleic acid. The gene is associated with type 1 diabetes (insulin dependent diabetes mellitus), and experimental evidence provides indication that it is the IDDM susceptibility gene IDDM4. In various aspects the invention provides nucleic acid, including coding sequences, oligonucleotide primers and probes, polypeptides, pharmaceutical compositions, methods of diagnosis or prognosis, and other methods relating to and based on the gene, including methods of treatment of diseases in which the gene may be implicated, including autoimmune diseases, such as glomerulonephritis, diseases and disorders involving disruption of endocytosis and/or antigen presentation, diseases and disorders involving cytokine clearance and/or inflammation, viral infection, elevation of free fatty acids or hypercholesterolemia, osteoporosis, Alzheimer's disease, and diabetes.
    Type: Grant
    Filed: December 31, 2002
    Date of Patent: July 17, 2007
    Assignee: Merck & Co., Inc.
    Inventors: John A. Todd, John W. Hess, Charles T. Caskey, Roger D Cox, David Gerhold, Holly Hammond, Patricia Hey, Yoshihiko Kawaguchi, Tony R. Merriman, Michael L. Metzker, Yusuke Nakagawa, Michael S. Phillips, Rebecca C. J. Twells
  • Patent number: 6995841
    Abstract: The present invention provides a technology called Pulse-Multiline Excitation or PME. This technology provides a novel approach to fluorescence detection with application for high-throughput identification of informative SNPs, which could lead to more accurate diagnosis of inherited disease, better prognosis of risk susceptibilities, or identification of sporadic mutations. The PME technology has two main advantages that significantly increase fluorescence sensitivity: (1) optimal excitation of all fluorophores in the genomic assay and (2) “color-blind” detection, which collects considerably more light than standard wavelength resolved detection. Successful implementation of the PME technology will have broad application for routine usage in clinical diagnostics, forensics, and general sequencing methodologies and will have the capability, flexibility, and portability of targeted sequence variation assays for a large majority of the population.
    Type: Grant
    Filed: August 28, 2001
    Date of Patent: February 7, 2006
    Assignees: Rice University, Baylor College of Medicine
    Inventors: Graham B. I. Scott, Carter Kittrell, Robert F. Curl, Michael L. Metzker